Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of our study is to investigate whether the substitution of the standard locking solution with a locking solution containing taurolidine and urokinase weekly (Taurolock ™ U 25,000 - www.taurolock.com ) reduces the rate of catheter dysfunction in hemodialysis patients with a history of TCC dysfunction requiring urokinase therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitair Ziekenhuis Brussel
• Treatments: Calcium heparin; Heparin; Taurolidine

Criteria

Inclusion Criteria:

• Adult, prevalent hemodialysis patients

• Informed and consented

• Hemodialysis 3x/week via a tunneled cuffed catheter

• Urokinase administration at least two times during the previous 6 months (with more than a week between 2 administrations)

• Adequate catheter function during the week before inclusion (defined by blood flow more than 250ml/min on each dialysis session and blood flow within 15% of the maximal blood flow after the last Urokinase administration)

Exclusion Criteria:

• Presence of heparin-induced thrombocytopenia

• Major hemorrhage or intracranial bleeding in the previous 3 months

• Pericarditis

• Intolerance to Taurolidine, citrate or to Urokinase

• Active catheter-related infection

• Catheter in the femoral vein